These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31222713)

  • 1. Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson S; Horvath Walsh LE; Wade RL
    Adv Ther; 2019 Aug; 36(8):1922-1935. PubMed ID: 31222713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia.
    Hagiwara M; Sharma A; Chung KC; Delea TE
    J Med Econ; 2018 Nov; 21(11):1119-1130. PubMed ID: 30122084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.
    Pandya BJ; Chen CC; McGuiness CB; Sullivan L; Feng Q; Walsh E; Borate U
    Expert Rev Hematol; 2022 Sep; 15(9):857-866. PubMed ID: 35924860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database.
    Brunner AM; Huggar D; Copher R; Zhou ZY; Zichlin ML; Anderson A; Downes N; McBride A
    Leuk Res; 2023 Sep; 132():107353. PubMed ID: 37562330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
    Solana-Altabella A; Boluda B; Rodríguez-Veiga R; Cano I; Acuña-Cruz E; Blanco A; Marco-Ayala J; de la Puerta R; Díaz-González Á; Piñana JL; Sanz J; Sempere A; Cervera J; Barragán E; Sargas C; Ballesta-López O; Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Montesinos P
    Eur J Haematol; 2021 May; 106(5):724-733. PubMed ID: 33609315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.
    Middeke JM; Herbst R; Parmentier S; Bug G; Hänel M; Stuhler G; Schäfer-Eckart K; Rösler W; Klein S; Bethge W; Bitz U; Büttner B; Knoth H; Alakel N; Schaich M; Morgner A; Kramer M; Sockel K; von Bonin M; Stölzel F; Platzbecker U; Röllig C; Thiede C; Ehninger G; Bornhäuser M; Schetelig J
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1491-1497. PubMed ID: 28527985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs.
    Meyers J; Yu Y; Kaye JA; Davis KL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):275-86. PubMed ID: 23677706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation.
    Preussler JM; Meyer CL; Mau LW; Majhail NS; Denzen EM; Edsall KC; Farnia SH; Saber W; Burns LJ; Vanness DJ
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):1021-1028. PubMed ID: 28263920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.
    Steckel NK; Groth C; Mikesch JH; Trenschel R; Ottinger H; Kordelas L; Mueller-Tidow C; Schliemann C; Reicherts C; Albring JC; Silling G; Schmidt E; Berdel WE; Lenz G; Ditschkowski M; Beelen DW; Stelljes M
    Br J Haematol; 2018 Mar; 180(6):840-853. PubMed ID: 29468631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.
    Kabra M; Margotto L; Manuguid F
    Future Oncol; 2021 Jul; 17(21):2769-2784. PubMed ID: 33881356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis.
    Wattanakamolkul K; Nakayama Y
    J Med Econ; 2022; 25(1):870-879. PubMed ID: 35703058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan.
    Huang HH; Chen CM; Wang CY; Hsu WW; Chen HM; Ko BS; Hsiao FY
    PLoS One; 2022; 17(1):e0261871. PubMed ID: 35061709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
    O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
    Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
    De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
    Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outcome of haploidentical hematopoietic stem cell transplantation for refractory/relapsed acute leukemia].
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Fu HX; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):917-21. PubMed ID: 23363748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
    Bell JA; Galaznik A; Farrelly E; Blazer M; Murty S; Ogbonnaya A; Eaddy M; Fram RJ; Faller DV; Kota V
    Leuk Res; 2018 Aug; 71():27-33. PubMed ID: 29944984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare expenses for treatment of acute myeloid leukemia.
    Bewersdorf JP; Shallis RM; Wang R; Huntington SF; Perreault S; Ma X; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):641-650. PubMed ID: 31159602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.